×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
BIOXCEL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of ...
WFLA
NEW ORLEANS, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 5,...
12 hours ago
STX FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages BioXcel Therapeutics (BTAI ...
mypanhandle.com
SAN FRANCISCO, CA / ACCESSWIRE / September 4, 2023 / Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ:BTAI) investors who suffered substantial losses...
13 hours ago
New Haven-based BioXcel Therapeutics announces $25M offering
Hartford Business Journal
BioXcel Therapeutics Inc., a New Haven-based biopharmaceutical company that uses artificial intelligence to develop medicines in...
1 month ago
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored ...
Yahoo Finance
Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University's Lombardi...
1 week ago
BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation
MarketWatch
By Colin Kellaher Shares of BioXcel Therapeutics jumped more than 20% in premarket trading Monday after the biopharmaceutical company said...
2 months ago
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
GlobeNewswire
NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing...
1 week ago
Bioxcel Therapeutics Advances SERENITY Trial and Strategy - TipRanks.com
Tipranks
Bioxcel Therapeutics Inc (BTAI) just unveiled an update. BioXcel Therapeutics, Inc. has unveiled an updated corporate overview and its business strategy,...
1 week ago
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
Yahoo Finance
Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA No FDA-approved...
1 week ago
BioXcel Therapeutics calls off proposed $60M public offering
Hartford Business Journal
Less than a week after announcing plans to raise $60 million from inventors, New Haven-based BioXcel Therapeutics Inc. said Tuesday it's calling off the...
2 months ago